The roadmap for antipsychotic psychopharmacology: an overview.
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000517:prevention & control; D001569:Benzodiazepines / Q000008:administration & dosage / Q000627:therapeutic use*; D015992:Body Mass Index; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D018492:Dopamine Antagonists / Q000009:adverse effects; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006634:Histamine H1 Antagonists / Q000009:adverse effects; D006801:Humans; D018727:Muscarinic Antagonists / Q000009:adverse effects; D000077152:Olanzapine; D011600:Psychopharmacology / Q000379:methods*; D043643:Receptor, Muscarinic M1 / Q000037:antagonists & inhibitors; D000072516:Retinoic Acid 4-Hydroxylase; D012559:Schizophrenia / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D006634:Histamine H1 Antagonists; D018727:Muscarinic Antagonists; D043643:Receptor, Muscarinic M1; D001569:Benzodiazepines; D003577:Cytochrome P-450 Enzyme System; D000072516:Retinoic Acid 4-Hydroxylase; D000077152:Olanzapine